EyeBiotech
CompanyUnited Kingdom
EyeBiotech develops one asset, in phase 3 (tiespectus in diabetic retinopathy). Mostly small molecule acting on VEGFA; based in the United Kingdom.
- 1
- Asset
- Furthest
- Phase 3
- 1
- Trial
- 2
- Signals
Pipeline
1Inhibits vascular endothelial growth factor to reduce retinal vascular permeability and edema
Phase 3, Small molecule, VEGFA, diabetic retinopathy, macular edema
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms1
- Trials1
- Signals3
- Similar companies6
Updated 7 Oct 2026 · 4 sources